<DOC>
	<DOCNO>NCT01430416</DOCNO>
	<brief_summary>This study two part , dose escalation dose expansion . For dose escalation , primary objective estimate maximum tolerate dose ( MTD ) AEB071 patient uveal melanoma . For dose expansion , primary objective characterize safety tolerability MTD AEB071 patient uveal melanoma .</brief_summary>
	<brief_title>Safety Efficacy AEB071 Metastatic Uveal Melanoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<criteria>Uveal melanoma biopsy proven metastatic disease Males females ≥ 18 year age Consent biopsy tumor Measurable disease accord RECIST version 1.1 WHO performance status ≤ 1 Patients abnormal laboratory value define protocol Patients receive treatment strong inducer inhibitor cytochrome P450 3A4 ( CYP3A4 ) discontinue prior study entry Patients impaired cardiac function clinically significant cardiac disease define protocol Patients another malignancy treat within last three year exception localize basal cell carcinoma cervical carcinoma Patients impairment gastrointestinal function disease Patients severe systemic infection Patients know HIV positive and/or active hepatitis B C infection Time since last therapy treatment underlying malignancy : Cytotoxic chemotherapy : ≤ duration recent cycle previous regimen ( minimum 2 week ) Nitrosurea : ≤ 6 week Biologic therapy : ≤ 4 week ≤ 5 x PK halflife small molecule therapeutic otherwise defined Patients undergone major surgery le 4 week prior enrollment fully recover prior surgery Women childbearing potential unless use highly effective method contraception dose least 36 hour last dose . Highly effective contraception define protocol . Patients primary central nervous system tumor brain metastasis . Pregnant nursing ( lactate ) woman . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Uveal melanoma</keyword>
	<keyword>phase 1</keyword>
	<keyword>AEB071</keyword>
	<keyword>Metastatic</keyword>
</DOC>